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Objective:  To  evaluate  the  immediate  improvement  rate  of  irritative  cough  in  patients  treated
with the  combination  of  Ananas  comosus  extract  and  honey  (Bromelin®)  compared  with  the  use
of honey  alone  (placebo  group).
Methods:  Pragmatic,  double-blind,  randomized,  parallel-group  study  with  children  aged
between 2  and  15  years,  with  irritative  cough  for  at  least  24hours.  The  double-blind  assess-
ment of  cough  was  through  the  number  of  observed  coughing  episodes  and  intensity  score  for
a period  of  10minutes  of  observation.  The  decrease  of  one  point  in  the  mean  total  score  was
considered  as  a  therapeutic  effect.
Results:  There  was  a  reduction  in  coughing  episodes  in  both  groups,  as  well  as  in  the  cough
score after  30minutes  of  drug  or  honey  administration.  The  change  in  clinical  score  above  two
points, which  could  indicate  marked  improvement,  occurred  in  ﬁve  patients  in  the  bromelin
group and  only  in  one  in  the  placebo  group,  but  without  signiﬁcant  difference.  There  were  no
adverse events.
Conclusions:  The  immediate  improvement  rate  of  irritative  cough  was  similar  in  patients
treated with  combination  of  Ananas  comosus  extract  and  honey  (Bromelin®)  compared  with
the use  of  honey  alone  (placebo  group).  It  is  possible  that  honey  has  a  therapeutic  effect  on
mucus and  cough  characteristics  (Clinical  Trials:  NCT01356693).
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Uso  do  mel  de  abelha  associado  ao  Ananas  comosus  (Bromelin)  no  tratamento
da  tosse  irritativa  aguda
Resumo
Objetivo:  Avaliar  a  taxa  de  melhoria  imediata  da  tosse  irritativa  em  pacientes  tratados  com
associac¸ão do  extrato  do  Ananas  comosus  em  mel  de  abelha  (Bromelin®)  e  compará-la  com  a
de uso  do  mel  isolado  (grupo  placebo).
Métodos:  Estudo  pragmático  da  vida  real,  duplo-cego,  randômico,  de  grupos  paralelos,  em
crianc¸as, entre  dois  e  15  anos,  com  tosse  irritativa  havia  pelo  menos  24  horas.  A  avaliac¸ão  da
tosse foi  duplo-cega  foi  feita  por  meio  da  avaliac¸ão  do  número  de  episódios  observáveis  e  do
escore de  intensidade  de  tosse  durante  o  período  de  10  minutos  de  observac¸ão.  A  reduc¸ão  de
um ponto  na  média  do  escore  total  foi  considerada  como  efeito  terapêutico.
Resultados:  Em  ambos  os  grupos  houve  reduc¸ão  do  número  de  episódios  de  tosse,  assim  como
do escore  de  tosse  após  30  minutos  de  administrac¸ão  do  medicamento  ou  do  mel.  A  mudanc¸a
de escore  clínico  superior  a  dois,  que  poderia  indicar  melhoria  acentuada,  ocorreu  em  cinco
pacientes do  grupo  com  bromelina  e  em  apenas  um  do  placebo,  mas  sem  diferenc¸a  signiﬁcante.
Não ocorreram  eventos  adversos.
Conclusões:  A  taxa  de  melhoria  imediata  da  tosse  irritativa  foi  similar  entre  pacientes  tratados
com associac¸ão  do  extrato  do  Ananas  comosus  em  mel  de  abelha  (Bromelin®)  e  com  o  uso  do  mel
isolado (grupo  placebo).  É  possível  que  haja  um  efeito  terapêutico  do  mel  nas  características
do muco  e  da  tosse  (Clinical  Trials:  NCT01356693).
© 2016  Sociedade  de  Pediatria  de  Sa˜o  Paulo.  Publicado  por  Elsevier  Editora  Ltda.  Este e´  um





























Viral  processes  of  the  airways  are  usually  self-limited  and
characterized  mainly  by  fever  and  coughing,  which  are  two
independent  predictors  of  the  virus  presence  and  tend  to
disappear  in  approximately  one  week.  However,  coughing
is  the  most  common  symptom  in  primary  care  physicians’
ofﬁces  and  is  a  frequent  cause  of  visits  to  emergency  care;
this  symptom  can  become  so  intense  to  the  point  of  leading
patient  and  relatives  to  exhaustion.1--3
In  such  cases,  symptomatic  drugs  are  often  used  by  the
patients  that  self-medicate,  often  in  response  to  advertise-
ment  and  the  fact  that  they  do  not  require  a  prescription.
Available  in  pharmacies  and  drugstores,  with  different  for-
mulations,  substances  for  cough  relief  can  bring  risks,
especially  in  the  pediatric  age  group.3,4
Dextromethorphan  and  diphenhydramine  are  often  used
as  antitussive  agents,  especially  in  children.5 A  clinical  study
compared  these  two  therapeutic  principles  with  honey,
regarding  the  control  of  nocturnal  cough  and  sleep  quality  of
children  with  irritative  cough,  and  found  that  honey  (2.5mL)
administered  before  sleep,  showed  better  results  regarding
symptom  relief  when  compared  with  these  two  drugs.6 A
recent  Cochrane  Library  review,  carried  out  with  clinical
studies  with  acceptable  methodological  quality  standards,
did  not  report  any  evidence  for  or  against  the  effective-
ness  of  these  drugs  in  the  symptomatic  relief  of  patients
with  cough.4 Therefore,  an  ideal  therapeutic  strategy  for
symptomatic  control  of  cough  remains  uncertain  to  date.3--5
Consequently,  the  individual  and  the  relatives  distressed
by  the  coughing  seek  measures  they  consider  safe  for  cough
relief,  when  this  symptom  is  intense.  In  this  aspect,  empir-
ical  therapy  based  on  natural  and/or  herbal  products,  has
a
i
teen  increasingly  employed  and  many  people  use  it  freely,
ith  or  without  medical  prescription,  secondary  to  the  rela-
ives’  suggestion  and/or  the  patient’s  own  beliefs.3
In  this  context,  products  derived  from  Ananas  comosus
xtract  (rich  in  Bromelin)  and  honey  have  shown  promis-
ng  results,  as  they  contain  proteolytic  enzymes  such  as
rypsin,  chymotrypsin  and  Bromelin.7 Bromelin  is  the  generic
ame  for  the  family  of  proteolytic  enzymes  containing  the
ulfhydryl  radical  derived  from  A.  comosus,  the  pineapple
lant,  which  also  has  nonproteolytic  enzymes,  with  signif-
cant  topical  action  in  the  respiratory  mucosa.7,8 Free  of
oxic  effects,  these  pineapple-derived  products  have  shown
romising  properties  in  in  vitro  studies:  they  interfere  with
he  growth  of  malignant  cells,  inhibit  platelet  aggregation
nd  coagulation  and  have  mainly  an  anti-inﬂammatory  and
ucolytic  action.  These  are  potentially  beneﬁcial  actions;
romelin  has  shown  to  have  a  signiﬁcant  action  in  dissolving
ronchial  secretion,  with  the  advantage  of  being  a  food  con-
tituent  and,  thus,  a  safe  substance  for  use  by  children.9--13
The  World  Health  Organization  indicates  honey  as  a
otential  treatment  of  cough  in  upper  respiratory  tract
nfections  in  children,  being  considered  a  symptomatic,
nexpensive,  popular  and  safe  treatment.  Studies  have
ttributed  antioxidant,  antibacterial,  antifungal,  antiviral,
nti-inﬂammatory  and  antitumor  actions  to  honey,  as  well  as
mmunomodulatory  properties.14--16 A  double-blind,  random-
zed  trial  evaluated  the  effectiveness  of  three  types  of  honey
eucalyptus,  citrus  and  labiatae)  in  the  control  of  nocturnal
ough  and  quality  of  sleep  in  children  with  upper  respiratory
ract  infections  and  compared  them  with  placebo.  The  three
ctive  treatment  regimens  with  honey  showed  signiﬁcant
mprovement  of  the  assessed  parameters  when  compared









































































































The  combination  of  A.  comosus  extract  with  honey  may
epresent  a  breakthrough  in  the  symptomatic  treatment,
ossibly  by  blocking  the  triggering  mechanisms  of  cough  due
o  viral  or  irritative  conditions.  Thus,  this  study  was  aimed
o  evaluate  the  effect  on  the  immediate  inhibition  of  irri-
ative  cough  in  patients  treated  with  a  combination  of  A.
omosus  (pineapple)  and  honey  (Bromelin®)  and  compare
hem  with  those  treated  with  honey  alone  (placebo)  in  a
ediatric  emergency  care  environment.
ethod
his  pragmatic,  real-life,  double-blind,  randomized  study
f  parallel  groups  was  carried  out  in  the  pediatric  service
f  Clinica  Amaury  Coutinho,  linked  to  Recife  City  Hall.
atients  in  the  active  group  (letter  A)  received  the  combi-
ation  of  honey  and  A.  comosus  extract  HBS19820501  (rich
n  Bromelin)  as  syrup  formulation  and  the  placebo  group
letter  B)  received  only  honey.  The  quality  of  the  honey
as  certiﬁed  in  both  groups  and  approved  by  the  regula-
ory  agencies  and  the  National  Health  Surveillance  Agency
Anvisa)  for  sale;  the  honey  had  been  recently  produced  and
nderwent  strict  bacteriological  control.  Randomization  was
arried  out  according  to  a  table  generated  by  Excel  program.
he  double-blinding  was  released  and  the  treatment  groups
ere  revealed  only  after  the  analysis  of  the  study  results.
Children  aged  between  two  and  15  years,  with  irrita-
ive  cough  for  at  least  24hours,  which  led  to  the  need  for
edical  consultation,  participated  in  the  study.  We  excluded
atients  with  a  history  of  obstructive  pulmonary  dis-
ase,  cystic  ﬁbrosis,  neuropathies,  heart  disease,  diabetes
nd  identiﬁable  primary  or  secondary  immunodeﬁciencies.
atients  should  have  acute  cough  due  to  viral  upper  airway
nfection,  thus  considered  due  to  the  presence  of  mild  fever
r  fever  associated  with  hyaline  or  catarrhal  rhinorrhea,
asting  less  than  72hours,  without  clinical  manifestations
f  associated  bronchospasm.  After  meeting  the  inclusion
riteria,  patients  were  randomly  assigned  to  a  treatment
roup  (Bromelin® or  honey).  The  patients’  parents  and/or
uardians  agreed  with  their  participation  and  signed  the
nformed  consent  form.  The  two  treatment  regimens  were
dministered  as  follows:  (a)  children  up  to  20kg  received
mL;  (b)  for  those  weighing>20kg,  1mL  was  administered
or  every  ﬁve  kilos  of  additional  weight.  Before  the  ran-
omization,  patients  with  detectable  bronchospasm  were
rescribed  -2  adrenergic  and,  if  necessary,  a  single-dose
f  oral  steroids  and  the  patient  was  considered  ineligible
or  the  study.  The  organoleptic  characteristics  of  Bromelin®
nd  honey  are  similar.
Patients’  evolution  and  clinical  data  after  treatment
ere  reported  in  a  standardized  clinical  report  form.  Cough
ssessment  was  carried  out  in  double-blind  fashion  by  one
f  the  investigators  by  counting  the  number  of  episodes
bserved  and  the  cough  intensity  score  during  a  10-min
bservation  period.  The  initial  and  ﬁnal  cough  intensity
core  was  classiﬁed  according  to  a  tool  as  0=absent;  1=mild,
=moderate;  3=intense;  4=very  intense,  according  to  a  pre-
ious  study.5 According  to  this  tool,  a  decrease  of  one
oint  in  the  mean  total  score  is  considered  as  therapeutic
ffect.  After  waiting  30minutes  post-drug  administration,
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bservation  period,  which  was  chosen  as  it  is  feasible  and
atisfactory  in  the  actual  clinical  setting  of  an  emergency
are  service.
Therefore,  after  the  coughing  episodes  observed  by
he  researcher  were  quantiﬁed  in  the  10minutes  prior  to
reatment  administration,  the  standardized  observation  was
epeated  30minutes  after  drug  administration,  again  in  a
ouble-blind  fashion.  All  evaluations  before  and  after  the
rug  or  placebo  administration  were  carried  out  by  a  single
nd  the  same  investigator  (physician)  in  a double-blind  fash-
on  (neither  the  investigator  nor  the  patient,  nor  the  family
new  which  product  was  used),  in  order  to  attain  robust
esults.
The  medication  safety  was  assessed  by  the  frequency  of
eported  adverse  events,  such  as  episodes  of  vomiting,  epi-
astric  and  abdominal  pain,  among  others.  The  monitoring
f  subsequent  adverse  events  was  not  performed.
To  calculate  sample  size,  the  following  was  considered:
ower  of  test  of  90%,  rate  of  cough  improvement  in  the
ctive  group  of  40%,  and  10%  in  the  placebo  group,  two-
ailed  hypothesis  test  and  5%  signiﬁcance  level.  Thus,  60
atients  were  necessary  to  assess  the  possible  therapeutic
ffects  of  the  active  treatment.  This  calculation  is  according
o  the  clinical  trial  by  Muller  et  al.,  who  studied  approxi-
ately  30  patients  per  group  to  assess  the  possible  effect  of
romelin  on  inﬂammatory  markers,  but  with  the  consequent
mpact  on  the  clinical  improvement  of  cough.8
Statistical  analysis  took  into  account  the  nature  of  the
ssessed  variables.  Numerical  variables  were  expressed  as
ean  and  standard  deviation  or,  when  necessary,  in  medi-
ns  and  25--75  percentiles,  whereas  categorical  ones  were
xpressed  as  percentages.  Numerical  variables  were  com-
ared  using  Student’s  t  test,  whereas  the  chi-square  test
as  used  for  categorical  ones.  The  value  was  considered
igniﬁcant  when  p<5%.
The  study  was  approved  by  the  Institutional  Review  Board
f  Centro  de  Ciências  da  Saúde  da  Universidade  Federal  de
ernambuco,  with  CAAE  n.  0311.0.172.000-10  and  the  trial
as  registered  at  Clinical  Trials  sob  under  n.  NCT01356693
ClinialTrials.gov  Identiﬁer).
esults
able  1  demonstrates  that  the  two  groups  of  patients  were
imilar  in  age,  gender,  days  of  coughing  and  mean  clinical
core  of  coughing  episodes.  Table  2  shows  that  both  groups
ad  a  reduction  in  coughing  episodes,  as  well  as  in  the
ough  score  30minutes  after  drug  or  honey  administration.
owever,  after  analyzing  the  change  in  clinical  score  higher
han  two  points,  which  could  indicate  a  more  accentuated
mprovement,  it  was  seen  to  have  occurred  in  ﬁve  patients
n  the  active  group  and  one  in  the  placebo  group.  There  were
o  immediate  adverse  events.
iscussion
hen  the  bronchial  mucosa  is  injured  by  chemical,  physi-
al  or  infectious  agents,  it  responds  with  an  inﬂammatory
rocess,  in  which  epithelial  cells  start  to  produce  excessive
mounts  of  mucus.17 After  a  viral  infection  occurs,  there
s  an  increase  in  the  release  of  cytokines,  neurotransmit-
Use  of  honey  associated  with  Ananas  comosus  (Bromelin)  in  the  treatment  of  acute  irritative  cough  415
Table  1  General  baseline  characteristics  of  the  Bromelin  and  Placebo  (honey)  study  groups  regarding  gender,  mean  age,  days
of symptom  persistence  and  initial  cough  severity  score.
Group p-value
Bromelin® (n=31)  Placebo  (n=29)
Gender  M/F  13/18  13/16  0.97a
Age  in  years--mean  (P25--P75)  5.3  (3.0--7.5)  5.6  (2.0--7.5)  0.82b
Days  of  symptoms  0.98a
1  6  6
2 10  9
3 15  14
Coughing episodes--median  (P25--P75) 3  (2--3) 3  (2--4) 0.98b
Cough  score--median 2  2  0.91b
Score>2,  n  (%)  26  (84%)  26  (90%)  0.87a
Days of symptoms, number of days with symptoms of cough before consultation; coughing episodes--median (P25--P75), number of
coughing episodes during the 10minutes of initial observation by the doctor; cough score--median, initial cough score observed by the
doctor (0=absent; 1=mild; 2=moderate; 3=intense; 4=very intense).
a Chi-square.
b Wilcoxon Test.
Table  2  Change  in  the  number  of  coughing  episodes  and  cough  scores  between  the  observation  periods  (10minutes)  before  and
30minutes after  administration  of  the  treatment  regimen  in  60  evaluated  patients.
Group p-value
Bromelin® (n=31)  Placebo  (n=29)
Coughing  episodes
Before  [Median  (P25--P75)]  3  (2--3)  3  (2--4)
After [Median  (P25--P75)]  1  (1--1)  1  (1--1)
Before-after  difference  (Mean±SD)  1.71±0.78  1.76±0.87  0.83a
Reduction  in  coughing  episodes  after  medication  (n)  0.94b
0  (no  change)  2  2
1 11  9
2 13  12
3 4  6
4 1  0
Before-after  difference  (Mean±SD)  −0.97±0.62  −0.86±0.45  0.32a
Variation  in  the  clinical  cough  score  after  the  medication 0.22b
0  (no  change)  6  6
−1 30  32










ca Student’s t test.
b Chi-square.
ters  and  leukotrienes,  which  induce  an  increase  in  neural
receptor  levels,  with  transient  stimulation  of  afferent  neural
activity,  mucus  hypersecretion  and,  possibly,  exacerbation
of  the  effects  on  cholinergic  motor  pathways.  The  feeling
of  irritation  that  precedes  the  cough  motor  action  allows
us  to  infer  the  concept  of  cough  syndrome  due  to  hyper-
sensitivity  after  acute  respiratory  viral  infection,  which,
in  some  patients,  becomes  a  refractory,  exhausting  cough
due  to  inﬂammation  and  excess  mucus.17 Although  diphen-
hydramine  and  dextromethorphan  are  the  most  commonly
used  drugs  in  the  management  of  irritative  cough,  they  have
not  been  shown  to  be  superior  to  placebo  in  controlling
this  symptom.18 On  the  other  hand,  a  comparative  study




eheir  equivalence,  with  honey  superiority  when  compared
ith  placebo-treated  patients.15
The  mucolytic  action  of  certain  drugs  can  promote  reduc-
ion  in  mucus  viscosity  and  facilitate  its  elimination  by
oughing  and  through  ciliary  beating  in  the  bronchial  epithe-
ium.  This  is  possible  due  to  the  breakdown  of  mucoproteins,
hich  splits  them  into  polypeptides.  Furthermore,  the  anti-
nﬂammatory  action  of  a  speciﬁc  drug  can  contribute  to  the
eduction  in  thick  mucus  production.7,17,19 The  extract  of  A.
omosus,  present  in  the  product  used  in  the  present  study,
ontains  proteolytic  enzymes  (Bromelin,  ribonuclease,  glu-
ose  oxidase,  invertase  and  diastase)  and  bivalent  cations
f  trace  elements  (magnesium,  manganese,  zinc,  iron  and
alcium)  that  act  as  cofactors  for  the  functions  of  these






















































































onds  by  incorporating  water  molecules,  thus  facilitating
he  ﬂuidization  of  thick  mucus.7,19
In  vitro  studies  indicate  that  the  anti-inﬂammatory  activ-
ty  of  Bromelin,  results  in  part  from  the  inhibition  of
radykinin  formation  at  the  inﬂammation  site,  through  the
epletion  of  plasma  kallikrein  levels,  as  well  as  the  reduction
f  intermediates  of  the  coagulation  cascade,  which  lim-
ts  the  formation  of  ﬁbrin.  Additionally,  Bromelin  reduces
eukocyte  migration,  as  well  as  the  expression  of  adhesion
olecules  (CD128)  to  blood  vessels.7,19,20 The  possible  ben-
ﬁcial  effect  of  Bromelin  may  be  due  to  an  integrated  series
f  actions  on  cells  and  cytokines,  such  as:  natural  killer
NK)  cell  activation,  increased  production  of  tumor  necro-
is  alpha  factor,  as  well  as  Interferon-gamma  (IFN-) several
nterleukins  (IL-1,  IL-2,  IL-6)  and  of  granulocyte-macrophage
olony-stimulating  factor  and  seems  capable  of  interrupt-
ng  the  continuous  activation  of  CD4+  lymphocytes,  which
aintain  the  inﬂammatory  process.21
Additionally,  in  healthy  humans,  oral  ingestion  of
romelin  promotes  a  change  in  the  circadian  cycle  of  IFN-
,  IL-5  and  IL-10,  suggesting  an  immunomodulatory  effect
n  T  lymphocytes.21 This  observation  has  been  the  ratio-
ale  for  the  use  of  Bromelin,  either  alone  or  associated  with
ther  natural  products  in  the  treatment  of  autoimmune  and
nﬂammatory  diseases,  such  as  ulcerative  colitis,  multiple
clerosis  and  respiratory  tract  disorders.21,22 In  children  with
cute  sinusitis,  Bromelin  was  added  to  the  standard  therapy
nd  there  was  a  signiﬁcant  reduction  in  symptom  dura-
ion  and  time  of  recovery,  when  compared  with  those  who
eceived  only  the  conventional  treatment;  it  is  extremely
afe,  with  only  a  mild  and  self-limiting  allergic  reaction  in  a
atient  allergic  to  pineapple.13
Honey  was  the  common  constituent  of  the  two  forms  of
reatment,  which  leads  us  to  believe  that  the  mucolytic  and
ough  relief  properties  of  honey  were  responsible  for  the
eduction  in  the  cough  score,  as  well  as  the  reduction  in  the
umber  of  coughing  episodes  observed  in  the  two  groups
f  assessed  patients.15,23 The  literature  has  suggested  that
oney  may  be  indicated  as  a  rational  measure  in  the  treat-
ent  of  cough,  as  it  is  low  cost,  has  rare  adverse  events  and
here  is  some  evidence  of  a  possible  therapeutic  action.16,24
This  clinical  trial  suggests  that,  considering  the  patent
mprovement  in  both  groups,  there  probably  is  a  therapeutic
ffect  of  honey  on  mucus  and  cough  characteristics,  which
ay  have  made  it  difﬁcult  to  identify  differences  when
oney  is  associated  with  the  possible  additional  pharma-
ological  and  favorable  action  of  Bromelin.  The  suggested
ypothesis  is  that  the  sweetness  of  honey  itself  promotes
alivation  and  secretion  production  in  the  airways  and  leads
o  mucus  liquefaction,  reducing  cough  due  to  the  lower
rritation  in  the  larynx  and  pharynx  and,  most  importantly,
ith  no  side  effects,  so  it  can  be  safely  used  in  children
lder  than  one  year,  when  the  intestinal  microbiome  is
tructured  and  deﬁned  and  there  is  adequate  immunity
gainst  Clostridium  botulinum, a  possible  contaminant  of
oney.16,25,26 In  a  multicenter  trial  carried  out  in  Europe,
oney  was  used  in  children  aged  1  to  18  years  without  any
ide  effects  and  with  possible  therapeutic  beneﬁts.27The  present  study,  as  mentioned  before,  is  a  pragmatic
linical  trial  carried  out  in  a  real-life  scenario  of  an  emer-
ency  service,  which  may  have  created  some  limitations,
uch  as  the  need  to  use  more  objective  and  reproduciblePeixoto  DM  et  al.
ndicators  to  assess  cough  improvement,  especially  in  a  pop-
lation  of  children  with  such  a  wide  age  range  wide  for  the
nalysis  of  clinical  sign  caused  by  such  diverse  pathologies.
owever,  all  the  study  patients  had  acute  cough  associated
ith  upper  airway  infection  and,  additionally,  all  evaluations
ere  carried  out  in  double-blind  fashion  and  standardized
y  a  single  researcher,  allowing  an  internal  validation  of  the
tudy.  An  evaluation  method  using  video,  a  longer  time  of
bservation  and  a better-deﬁned  outline  of  existing  diseases
ould  be  ideal,  but  would  hinder  the  operational  assessment
n  a  representative  clinical  scenario  of  emergency  care.
The  addition  of  Bromelin  to  honey  does  not  result  in
n  additional  effect  in  the  treatment  of  irritative  cough.
t  seems  that  a  possible  effect  of  Bromelin,  if  any,  would
e  better  assessed  by  using  another  substance  as  placebo,
ecause  honey  can  be  a  pharmacologically  active  substance
n  coughing.25--27 Similarly,  new  clinical  trials  with  a  longer
bservation  period,  assessing  other  outcomes  are  necessary
o  evaluate  this  potential  therapeutic  effect  of  honey,  either
lone  or  associated,  on  irritative  cough.  In  daily  clinical
ractice,  parents,  relatives  and  patients  are  interested  in
his  explanation  with  some  urgency,  considering  their  care
nd  safety  and  the  possibility  of  relief  for  the  annoyance
hat  irritating  cough  causes  to  patients.16,25,26
unding
ebron  Indústrias  Químicas.
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